| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Suzana Uzun, Oliver Kozumplik, Ninoslav Mimica, Vera Folnegović-Smal. Aripiprazole: an overview of a novel antipsychotic. Psychiatria Danubina. vol 17. issue 1-2. 2006-02-15. PMID:16395846. |
aripiprazole has demonstrated superiority to placebo in clinical studies of the treatment of both schizophrenia and acute bipolar mania. |
2006-02-15 |
2023-08-12 |
Not clear |
| Natalie C Edwards, Julie C Locklear, Marcia F T Rupnow, Ronald J Diamon. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. PharmacoEconomics. vol 23 Suppl 1. 2006-01-31. PMID:16416763. |
the objective of this study was to assess the cost effectiveness of long-acting risperidone, oral risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, and haloperidol depot in patients with schizophrenia over 1 year from a healthcare system perspective. |
2006-01-31 |
2023-08-12 |
Not clear |
| Jan Volavka, Pal Czobor, Leslie Citrome, Robert D McQuade, William H Carson, Dusan Kostic, Sterling Hardy, Ronald Marcu. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. The Journal of clinical psychiatry. vol 66. issue 11. 2006-01-30. PMID:16420071. |
efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. |
2006-01-30 |
2023-08-12 |
Not clear |
| Marc Ziegenbein, Marcel Sieberer, Iris T Calliess, Stefan Krop. Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. The Australian and New Zealand journal of psychiatry. vol 39. issue 9. 2006-01-11. PMID:16168043. |
combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. |
2006-01-11 |
2023-08-12 |
Not clear |
| R Bridle. [Aripiprazole in the treatment of schizophrenia]. Praxis. vol 94. issue 23. 2005-12-15. PMID:16001540. |
[aripiprazole in the treatment of schizophrenia]. |
2005-12-15 |
2023-08-12 |
Not clear |
| Thomas P Beresford, Lori Clapp, Brandon Martin, John L Wiberg, Julie Alfers, Henry F Beresfor. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. Journal of clinical psychopharmacology. vol 25. issue 4. 2005-12-06. PMID:16012280. |
aripiprazole in schizophrenia with cocaine dependence: a pilot study. |
2005-12-06 |
2023-08-12 |
human |
| Aripiprazole: new drug. Just another neuroleptic. Prescrire international. vol 14. issue 79. 2005-11-22. PMID:16285069. |
(2) aripiprazole is a new neuroleptic licensed for the treatment of schizophrenia. |
2005-11-22 |
2023-08-12 |
rat |
| Aripiprazole: new drug. Just another neuroleptic. Prescrire international. vol 14. issue 79. 2005-11-22. PMID:16285069. |
(4) in a double-blind trial lasting 6 months, aripiprazole 15 mg/day was more effective than placebo in preventing acute relapses of schizophrenia (34% versus 57%), but the clinical relevance of the combined endpoint used to define relapse is unclear. |
2005-11-22 |
2023-08-12 |
rat |
| Aripiprazole: new drug. Just another neuroleptic. Prescrire international. vol 14. issue 79. 2005-11-22. PMID:16285069. |
(11) in practice, there are too many unanswered questions to recommend aripiprazole for patients with schizophrenia. |
2005-11-22 |
2023-08-12 |
rat |
| Elmer López-Meza, Angel Ruiz-Chow, Jesus Ramirez-Bermude. Aripiprazole in psychosis associated with Parkinson's disease. The Journal of neuropsychiatry and clinical neurosciences. vol 17. issue 3. 2005-11-14. PMID:16179668. |
aripiprazole is an agent for treating schizophrenia. |
2005-11-14 |
2023-08-12 |
Not clear |
| Franca Centorrino, Kate V Fogarty, Paola Cimbolli, Paola Salvatore, Terri-Ann Thompson, Gabriele Sani, Stephanie L Cincotta, Ross J Baldessarin. Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. Journal of psychiatric practice. vol 11. issue 4. 2005-10-04. PMID:16041234. |
aripiprazole is the first dopamine d2 receptor partial-agonist approved for treatment of schizophrenia. |
2005-10-04 |
2023-08-12 |
Not clear |
| Yoshihiro Tadori, Takashi Miwa, Katsura Tottori, Kevin D Burris, Arlene Stark, Toyoki Mori, Tetsuro Kikuch. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. European journal of pharmacology. vol 515. issue 1-3. 2005-08-16. PMID:15894311. |
aripiprazole's low intrinsic activities may account for the clinical finding that, unlike the other partial agonists, it is substantially active against both positive and negative symptoms of schizophrenia. |
2005-08-16 |
2023-08-12 |
human |
| M J Travis, T Burns, S Dursun, T Fahy, S Frangou, R Gray, P M Haddad, R Hunter, D M Taylor, A H Youn. Aripiprazole in schizophrenia: consensus guidelines. International journal of clinical practice. vol 59. issue 4. 2005-07-18. PMID:15853869. |
aripiprazole in schizophrenia: consensus guidelines. |
2005-07-18 |
2023-08-12 |
Not clear |
| M J Travis, T Burns, S Dursun, T Fahy, S Frangou, R Gray, P M Haddad, R Hunter, D M Taylor, A H Youn. Aripiprazole in schizophrenia: consensus guidelines. International journal of clinical practice. vol 59. issue 4. 2005-07-18. PMID:15853869. |
aripiprazole is a newly available atypical antipsychotic for the treatment of schizophrenia. |
2005-07-18 |
2023-08-12 |
Not clear |
| M J Travis, T Burns, S Dursun, T Fahy, S Frangou, R Gray, P M Haddad, R Hunter, D M Taylor, A H Youn. Aripiprazole in schizophrenia: consensus guidelines. International journal of clinical practice. vol 59. issue 4. 2005-07-18. PMID:15853869. |
the purpose of these guidelines is to outline the consensus reached by the schizophrenia innovation working group on best practice in prescribing and appropriate use of aripiprazole in the uk. |
2005-07-18 |
2023-08-12 |
Not clear |
| Mike Laune. Partial dopamine agonists in schizophrenia. Hospital medicine (London, England : 1998). vol 66. issue 5. 2005-07-05. PMID:15920862. |
aripiprazole (abilify) is the first of these compounds for the treatment of schizophrenia to be launched in the uk. |
2005-07-05 |
2023-08-12 |
Not clear |
| Mike Laune. Partial dopamine agonists in schizophrenia. Hospital medicine (London, England : 1998). vol 66. issue 5. 2005-07-05. PMID:15920862. |
aripiprazole has a promising efficacy and favourable tolerability profile that suggests it has a significant role to play in the management of schizophrenia. |
2005-07-05 |
2023-08-12 |
Not clear |
| Leslie Citrome, Richard Josiassen, Nigel Bark, Daniel E Salazar, Suresh Mallikaarju. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. Journal of clinical pharmacology. vol 45. issue 1. 2005-04-08. PMID:15601809. |
therapeutic doses of lithium and divalproex had no clinically significant effects on the pharmacokinetics of aripiprazole in patients with schizophrenia or schizoaffective disorder. |
2005-04-08 |
2023-08-12 |
Not clear |
| Dieter Naber, Martin Lamber. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 8. 2005-03-07. PMID:15588748. |
in phase iii comparative clinical studies, aripiprazole 15-30 mg/day was at least as effective as haloperidol and risperidone in short term treatment of acute exacerbation of schizophrenia but superior to haloperidol in long term maintenance therapy. |
2005-03-07 |
2023-08-12 |
Not clear |
| Dieter Naber, Martin Lamber. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 8. 2005-03-07. PMID:15588748. |
consistent with an atypical profile, aripiprazole is effective against positive, negative and cognitive symptoms of schizophrenia and has a favourable side effect profile with the incidence of extrapyramidal symptoms (eps) comparable to placebo. |
2005-03-07 |
2023-08-12 |
Not clear |